Prescribing information

 

   

Sacubitril/valsartan is recognised nationally by the CaReMe UK Partnership as a first-line treatment option for chronic HFrEF, to be given in combination with a beta-blocker and MRA.1

Entresto CaReMe award

 

 

ENTRESTO and the CaReMe UK Partnership

Watch Professor Iain Squire and Dr Jim Moore, board members of CaReMe UK, discuss the need for a ‘modern’ HF management algorithm, as well as the rationale for positioning sacubitril/valsartan as a first-line treatment option.1

 

Speaker Disclosures – Dr Jim Moore has received honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk and Roche for various activities including attending and participating in educational events and advisory boards, (National Cardiac Pathways Improvement Programme – Clinical Leadership Group, Observer on the British Society for Heart Failure Board, Member of the National Heart Failure Audit Domain Expert Group, NICE Guideline Committee member – Chronic Heart Failure 2018).

Professor Iain Squire has received honoraria for participating in educational activities and/or advisory boards for Novartis, Vifor Pharma and Boehringer Ingelheim. His employer has received funding for research from Novartis, Vifor Pharma, Boehringer Ingelheim, Merck and AstraZeneca.

 

For full guidance on managing your chronic HFrEF patients with ENTRESTO, download the full algorithm

down pointing arrow icon

 
 

See how starting with ENTRESTO is as simple as starting with an ACEi (enalapril)*†2,3

down pointing arrow icon

 

 

ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.2

Please click here for safety information

* CaReMe UK Partnership is a collaboration between the British Cardiovascular Society, the Renal Association, the Association of British Clinical Diabetologists, the Primary Care Cardiovascular Society and the Primary Care Diabetes Society.
† ENTRESTO contains valsartan, and therefore should not be coadministered with another ARB-containing product. Stop using an ACE inhibitor for 36 hours before starting ENTRESTO.2

ACE, angiotensin-converting enzyme; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist.

References:

  1. CaReMe UK Partnership. Modified from Management algorithm for NICE guideline “Chronic Heart Failure in Adults: diagnosis & management”. Available at: https://www.nice.org.uk/guidance/ng106. (Accessed September 2021).
  2. ENTRESTO Summary of Product Characteristics. Electronic medicines compendium website, UK. Available at: https://www.medicines.org.uk/emc/product/7751/smpc. (Accessed September 2021).
  3. Enalapril Summary of Product Characteristics. Electronic medicines compendium website, UK. Available at: https://www.medicines.org.uk/emc/product/6105/smpc. (Accessed September 2021).
Rate this content: 
No votes yet
UK | October 2021 | 125640-1
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]